UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
------------------------
FORM 10-K
------------------------
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 1999
There were 18,860,632 shares of Registrant's Common Stock issued and outstanding as of March
21, 2000.
---------------------------------------------------------------------
Source Site (EDGAR):
10-Q
Excerpt From
TYPE: 10-Q
SEQUENCE: 1
DESCRIPTION: FORM 10-Q
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934.
For the quarterly period ended September 30, 1999
As of November 1, 1999 there were 18,722,112 shares of Common Stock outstanding.
----------------------------------------------------------------------
Source Site (EDGAR):
424B1
Excerpt From
|
KERAVISION INC /CA/
Form: 424B1 Filing Date: 8/13/99 |
The Offering
Common stock offered by KeraVision.................. 4,000,000 shares
Common stock to be outstanding after this offering.. 18,078,476 shares
Use of proceeds..................................... We intend to use the net
proceeds of this offering
for the expansion of our
sales force and marketing
effort associated with
the U.S. launch of
Intacs, the continued
development and clinical
testing of additional
products based on our
Intacs technology, the
prepayment of short-term
debt and for working
capital and general
corporate purposes.
Dividend policy..................................... We intend to retain any
future earnings and we do
not anticipate paying
dividends on our common
stock in the foreseeable
future.
Risk factors........................................ For a discussion of
certain considerations
relevant to an investment
in our common stock, see
"Risk Factors."
Nasdaq National Market symbol....................... KERA
The number of shares of common stock to be outstanding after this offering is
based on the 14,078,476 shares outstanding at June 30, 1999 and the 4,000,000
shares of common stock being sold by us in this offering and excludes:
. 1,579,778 shares of common stock issuable upon exercise of options
outstanding at June 30, 1999 at a weighted average exercise price of
$7.43 per share and 2,268,719 shares reserved for future grants under our
stock option plans;
. 55,492 shares of common stock issuable upon exercise of a warrant held by
a financial institution with an exercise price of $10.81 per share;
. 2,122,856 shares issuable upon conversion of the shares of Series B
preferred stock outstanding as of June 30, 1999; and
. any shares of common stock that may be sold by us to the underwriters
pursuant to the over-allotment option.
---------------------------------------------------------------------------------